Modification of Sample Size in Group Sequential Clinical Trials
Authors:
- 1 September 1999
- journal article
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 55 (3) , 853-857
Abstract
Summary. In group sequential clinical trials, sample size reestimation can be a complicated issue when it allows for change of sample size to be influenced by an observed sample path. Our simulation studies show that increasing sample size based on an interim estimate of the treatment difference can substantially inflate the probability of type I error in most practical situations. A new group sequential test procedure is developed by modifying the weights used in the traditional repeated significance two‐sample mean test. The new test has the type I error probability preserved at the target level and can provide a substantial gain in power with the increase of sample size. Generalization of the new procedure is discussed.Keywords
This publication has 10 references indexed in Scilit:
- Designed Extension of Studies Based on Conditional Power1995
- Sample Size Reestimation for Triple Blind Clinical TrialsDrug Information Journal, 1993
- Interim analyses for monitoring clinical trials that do not materially affect the type I error rateStatistics in Medicine, 1992
- Sample size re-estimation without unblinding for normally distributed outcomes with unknown varianceCommunications in Statistics - Theory and Methods, 1992
- The role of internal pilot studies in increasing the efficiency of clinical trialsStatistics in Medicine, 1990
- The B-Value: A Tool for Monitoring DataBiometrics, 1988
- Discrete Sequential Boundaries for Clinical TrialsBiometrika, 1983
- Interim Analyses for Randomized Clinical Trials: The Group Sequential Approach1982
- A Multiple Testing Procedure for Clinical TrialsBiometrics, 1979
- Group sequential methods in the design and analysis of clinical trialsBiometrika, 1977